Compare · SNN vs SNOA
SNN vs SNOA
Side-by-side comparison of Smith & Nephew SNATS Inc. (SNN) and Sonoma Pharmaceuticals Inc. (SNOA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. SNN focuses on Industrial Specialties, while SNOA focuses on Medical/Dental Instruments.
- SNN is the larger of the two at $12.77B, about 3040.1x SNOA ($4.2M).
- SNN has been more active in the news (4 items in the past 4 weeks vs 3 for SNOA).
- SNN has more recent analyst coverage (25 ratings vs 0 for SNOA).
- Company
- Smith & Nephew SNATS Inc.
- Sonoma Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $12.77B
- $4.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2007
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 0
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Latest SNN
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form S-8 filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
- Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
- Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
Latest SNOA
- SEC Form S-3 filed by Sonoma Pharmaceuticals Inc.
- Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax
- SEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.
- Amendment: SEC Form 8-A12B/A filed by Sonoma Pharmaceuticals Inc.
- SEC Form 8-K filed by Sonoma Pharmaceuticals Inc.
- Sonoma Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
- SEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.
- SEC Form DEF 14A filed by Sonoma Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Sonoma Pharmaceuticals Inc.